By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...
The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...
Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
The Catalysis group at Boehringer Ingelheim works with various internal and external partners to develop synthetic technologies that speed up the delivery of lifesaving drugs to patients. The webinar ...
Medpage Today on MSN2d
Potentially Large Cost Savings With Home-Based OCT for Neovascular AMDCHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...
Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace environment.
An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...
AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker ...
Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback